Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2010

Open Access 01-12-2010 | Research article

Neuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans

Authors: Roongpetch Keowkase, Marwa Aboukhatwa, Bao-Ling Adam, J Warren Beach, Alvin V Terry Jr, Jerry J Buccafussco, Yuan Luo

Published in: Molecular Neurodegeneration | Issue 1/2010

Login to get access

Abstract

Background

Our previous work indicated that novel analogs of choline have cytoprotective effects in vitro that might be useful in neurodegenerative conditions such as Alzheimer's disease (AD). Furthermore, two lead compounds (JWB1-84-1 and JAY2-22-33) from a library of more than 50 improved cognitive performances in a transgenic mouse model of AD. The purpose of these experiments was to more specifically investigate the neuroprotective capabilities of these lead compounds both in vitro and in vivo.

Results

We used N2a cells which express a Swedish mutation in the amyloid precursor protein and presenilin 1 genes to investigate the effect of JWB1-84-1 and JAY2-22-33 on β-amyloid (Aβ) levels and found that both compounds significantly reduced Aβ levels. JWB1-84-1 and JAY2-22-33 also protected rat primary cortical neurons from Aβ toxicity. Subsequently, we utilized the nematode Caenorhabditis elegans (C. elegans) as an in vivo model organism to identify potential molecular targets of these compounds. In the C. elegans model of Aβ toxicity, human Aβ is expressed intracellularly in the body wall muscle. The expression and subsequent aggregation of Aβ in the muscle leads to progressive paralysis.

Conclusion

We found that JAY2-22-33 (but not JWB1-84-1) significantly reduced Aβ toxicity by delaying paralysis and this protective effect required both the insulin signaling pathway and nicotinic acetylcholine receptors (nAChRs).
Appendix
Available only for authorised users
Literature
2.
go back to reference Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368 (9533): 387-403. 10.1016/S0140-6736(06)69113-7.PubMedCrossRef Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368 (9533): 387-403. 10.1016/S0140-6736(06)69113-7.PubMedCrossRef
3.
4.
go back to reference Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med. 2010, 362 (4): 329-44. 10.1056/NEJMra0909142.PubMedCrossRef Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med. 2010, 362 (4): 329-44. 10.1056/NEJMra0909142.PubMedCrossRef
5.
go back to reference Rezvani AH, Levin ED: Cognitive effects of nicotine. Biol Psychiatry. 2001, 49 (3): 258-67. 10.1016/S0006-3223(00)01094-5.PubMedCrossRef Rezvani AH, Levin ED: Cognitive effects of nicotine. Biol Psychiatry. 2001, 49 (3): 258-67. 10.1016/S0006-3223(00)01094-5.PubMedCrossRef
6.
go back to reference Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B: Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J. 2007, 21 (1): 61-73. 10.1096/fj.06-5841com.PubMedCrossRef Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B: Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J. 2007, 21 (1): 61-73. 10.1096/fj.06-5841com.PubMedCrossRef
7.
go back to reference Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA: Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease. Neurobiol Aging. 2009, 4: 15- Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA: Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease. Neurobiol Aging. 2009, 4: 15-
8.
go back to reference Buckingham SD, Jones AK, Brown LA, Sattelle DB: Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev. 2009, 61 (1): 39-61. 10.1124/pr.108.000562.PubMedPubMedCentralCrossRef Buckingham SD, Jones AK, Brown LA, Sattelle DB: Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev. 2009, 61 (1): 39-61. 10.1124/pr.108.000562.PubMedPubMedCentralCrossRef
9.
go back to reference Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT: Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci. 2010, 30 (7): 2442-53. 10.1523/JNEUROSCI.5038-09.2010.PubMedPubMedCentralCrossRef Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT: Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci. 2010, 30 (7): 2442-53. 10.1523/JNEUROSCI.5038-09.2010.PubMedPubMedCentralCrossRef
10.
go back to reference Papke RL, Bencherif M, Lippiello P: An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett. 1996, 213 (3): 201-4.PubMedCrossRef Papke RL, Bencherif M, Lippiello P: An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett. 1996, 213 (3): 201-4.PubMedCrossRef
11.
go back to reference Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX: Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. 1997, 9 (12): 2734-42. 10.1111/j.1460-9568.1997.tb01702.x.PubMedCrossRef Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX: Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. 1997, 9 (12): 2734-42. 10.1111/j.1460-9568.1997.tb01702.x.PubMedCrossRef
12.
go back to reference Jonnala RR, Graham JH, Terry AV, Beach JW, Young JA, Buccafusco JJ: Relative levels of cytoprotection produced by analogs of choline and the role of alpha7-nicotinic acetylcholine receptors. Synapse. 2003, 47 (4): 262-9. 10.1002/syn.10176.PubMedCrossRef Jonnala RR, Graham JH, Terry AV, Beach JW, Young JA, Buccafusco JJ: Relative levels of cytoprotection produced by analogs of choline and the role of alpha7-nicotinic acetylcholine receptors. Synapse. 2003, 47 (4): 262-9. 10.1002/syn.10176.PubMedCrossRef
13.
go back to reference Buccafusco JJ: Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interv. 2004, 4 (5): 285-95. 10.1124/mi.4.5.8.PubMedCrossRef Buccafusco JJ: Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interv. 2004, 4 (5): 285-95. 10.1124/mi.4.5.8.PubMedCrossRef
14.
go back to reference Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ: The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology. 2007, 53 (5): 588-600. 10.1016/j.neuropharm.2007.06.028.PubMedCrossRef Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ: The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology. 2007, 53 (5): 588-600. 10.1016/j.neuropharm.2007.06.028.PubMedCrossRef
15.
go back to reference Teschendorf D, Link CD: What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. Mol Neurodegener. 2009, 4: 38-10.1186/1750-1326-4-38.PubMedPubMedCentralCrossRef Teschendorf D, Link CD: What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. Mol Neurodegener. 2009, 4: 38-10.1186/1750-1326-4-38.PubMedPubMedCentralCrossRef
16.
go back to reference Gotz J, Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008, 9 (7): 532-44. 10.1038/nrn2420.PubMedCrossRef Gotz J, Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008, 9 (7): 532-44. 10.1038/nrn2420.PubMedCrossRef
17.
go back to reference Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G: Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem. 2003, 86 (1): 165-72. 10.1046/j.1471-4159.2003.01809.x.PubMedCrossRef Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G: Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem. 2003, 86 (1): 165-72. 10.1046/j.1471-4159.2003.01809.x.PubMedCrossRef
18.
go back to reference Faber PW, Alter JR, MacDonald ME, Hart AC: Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA. 1999, 96 (1): 179-84. 10.1073/pnas.96.1.179.PubMedPubMedCentralCrossRef Faber PW, Alter JR, MacDonald ME, Hart AC: Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA. 1999, 96 (1): 179-84. 10.1073/pnas.96.1.179.PubMedPubMedCentralCrossRef
19.
go back to reference Link CD: C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol. 2006, 41 (10): 1007-13. 10.1016/j.exger.2006.06.059.PubMedCrossRef Link CD: C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol. 2006, 41 (10): 1007-13. 10.1016/j.exger.2006.06.059.PubMedCrossRef
20.
go back to reference McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI: The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem. 2009, 284 (34): 22697-702. 10.1074/jbc.C109.028514.PubMedPubMedCentralCrossRef McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI: The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem. 2009, 284 (34): 22697-702. 10.1074/jbc.C109.028514.PubMedPubMedCentralCrossRef
21.
go back to reference Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A: Opposing activities protect against age-onset proteotoxicity. Science. 2006, 313 (5793): 1604-10. 10.1126/science.1124646.PubMedCrossRef Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A: Opposing activities protect against age-onset proteotoxicity. Science. 2006, 313 (5793): 1604-10. 10.1126/science.1124646.PubMedCrossRef
22.
go back to reference Keowkase R, Aboukhatwa M, Luo Y: Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology. 2010, 59 (4-5): 358-65. 10.1016/j.neuropharm.2010.04.008.PubMedPubMedCentralCrossRef Keowkase R, Aboukhatwa M, Luo Y: Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology. 2010, 59 (4-5): 358-65. 10.1016/j.neuropharm.2010.04.008.PubMedPubMedCentralCrossRef
23.
go back to reference van Marum RJ: Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol. 2008, 22 (3): 265-74. 10.1111/j.1472-8206.2008.00578.x.PubMedCrossRef van Marum RJ: Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol. 2008, 22 (3): 265-74. 10.1111/j.1472-8206.2008.00578.x.PubMedCrossRef
24.
25.
go back to reference Mukhopadhyay A, Oh SW, Tissenbaum HA: Worming pathways to and from DAF-16/FOXO. Exp Gerontol. 2006, 41 (10): 928-34. 10.1016/j.exger.2006.05.020.PubMedCrossRef Mukhopadhyay A, Oh SW, Tissenbaum HA: Worming pathways to and from DAF-16/FOXO. Exp Gerontol. 2006, 41 (10): 928-34. 10.1016/j.exger.2006.05.020.PubMedCrossRef
26.
go back to reference Murphy CT: The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. Exp Gerontol. 2006, 41 (10): 910-21. 10.1016/j.exger.2006.06.040.PubMedCrossRef Murphy CT: The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. Exp Gerontol. 2006, 41 (10): 910-21. 10.1016/j.exger.2006.06.040.PubMedCrossRef
27.
go back to reference Schaffitzel E, Hertweck M: Recent aging research in Caenorhabditis elegans. Exp Gerontol. 2006, 41 (6): 557-63. 10.1016/j.exger.2006.02.008.PubMedCrossRef Schaffitzel E, Hertweck M: Recent aging research in Caenorhabditis elegans. Exp Gerontol. 2006, 41 (6): 557-63. 10.1016/j.exger.2006.02.008.PubMedCrossRef
28.
go back to reference Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P: Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002, 99 (19): 12197-202. 10.1073/pnas.182425199.PubMedPubMedCentralCrossRef Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P: Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002, 99 (19): 12197-202. 10.1073/pnas.182425199.PubMedPubMedCentralCrossRef
29.
go back to reference Mousavi M, Hellstrom-Lindahl E: Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int. 2009, 54 (3-4): 237-44. 10.1016/j.neuint.2008.12.001.PubMedCrossRef Mousavi M, Hellstrom-Lindahl E: Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int. 2009, 54 (3-4): 237-44. 10.1016/j.neuint.2008.12.001.PubMedCrossRef
30.
go back to reference Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM: Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 2007, 190 (3): 269-319. 10.1007/s00213-006-0441-0.CrossRef Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM: Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 2007, 190 (3): 269-319. 10.1007/s00213-006-0441-0.CrossRef
31.
go back to reference White HK, Levin ED: Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl). 2004, 171 (4): 465-71. 10.1007/s00213-003-1614-8.CrossRef White HK, Levin ED: Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl). 2004, 171 (4): 465-71. 10.1007/s00213-003-1614-8.CrossRef
32.
go back to reference Sabbagh MN, Walker DG, Reid RT, Stadnick T, Anand K, Lue LF: Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neurosci Lett. 2008, 448 (2): 217-20.PubMedCrossRef Sabbagh MN, Walker DG, Reid RT, Stadnick T, Anand K, Lue LF: Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neurosci Lett. 2008, 448 (2): 217-20.PubMedCrossRef
33.
go back to reference Kaletta T, Hengartner MO: Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov. 2006, 5 (5): 387-98. 10.1038/nrd2031.PubMedCrossRef Kaletta T, Hengartner MO: Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov. 2006, 5 (5): 387-98. 10.1038/nrd2031.PubMedCrossRef
35.
go back to reference Townsend M, Mehta T, Selkoe DJ: Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007, 282 (46): 33305-12. 10.1074/jbc.M610390200.PubMedCrossRef Townsend M, Mehta T, Selkoe DJ: Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007, 282 (46): 33305-12. 10.1074/jbc.M610390200.PubMedCrossRef
36.
go back to reference Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL: Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem. 2009, 284 (28): 18742-53. 10.1074/jbc.M109.011015.PubMedPubMedCentralCrossRef Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL: Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem. 2009, 284 (28): 18742-53. 10.1074/jbc.M109.011015.PubMedPubMedCentralCrossRef
37.
go back to reference Morcos M, Hutter H: The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. J Alzheimers Dis. 2009, 16 (4): 897-908.PubMed Morcos M, Hutter H: The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. J Alzheimers Dis. 2009, 16 (4): 897-908.PubMed
38.
go back to reference Hsu AL, Murphy CT, Kenyon C: Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science. 2003, 300 (5622): 1142-5. 10.1126/science.1083701.PubMedCrossRef Hsu AL, Murphy CT, Kenyon C: Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science. 2003, 300 (5622): 1142-5. 10.1126/science.1083701.PubMedCrossRef
39.
go back to reference Morley JF, Morimoto RI: Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol Biol Cell. 2004, 15 (2): 657-64. 10.1091/mbc.E03-07-0532.PubMedPubMedCentralCrossRef Morley JF, Morimoto RI: Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol Biol Cell. 2004, 15 (2): 657-64. 10.1091/mbc.E03-07-0532.PubMedPubMedCentralCrossRef
40.
go back to reference Steinkraus KA, Smith ED, Davis C, Carr D, Pendergrass WR, Sutphin GL, Kennedy BK, Kaeberlein M: Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans. Aging Cell. 2008, 7 (3): 394-404. 10.1111/j.1474-9726.2008.00385.x.PubMedPubMedCentralCrossRef Steinkraus KA, Smith ED, Davis C, Carr D, Pendergrass WR, Sutphin GL, Kennedy BK, Kaeberlein M: Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans. Aging Cell. 2008, 7 (3): 394-404. 10.1111/j.1474-9726.2008.00385.x.PubMedPubMedCentralCrossRef
41.
go back to reference Touroutine D, Fox RM, Von Stetina SE, Burdina A, Miller DM, Richmond JE: acr-16 encodes an essential subunit of the levamisole-resistant nicotinic receptor at the Caenorhabditis elegans neuromuscular junction. J Biol Chem. 2005, 280 (29): 27013-21. 10.1074/jbc.M502818200.PubMedCrossRef Touroutine D, Fox RM, Von Stetina SE, Burdina A, Miller DM, Richmond JE: acr-16 encodes an essential subunit of the levamisole-resistant nicotinic receptor at the Caenorhabditis elegans neuromuscular junction. J Biol Chem. 2005, 280 (29): 27013-21. 10.1074/jbc.M502818200.PubMedCrossRef
42.
go back to reference Ballivet M, Alliod C, Bertrand S, Bertrand D: Nicotinic acetylcholine receptors in the nematode Caenorhabditis elegans. J Mol Biol. 1996, 258 (2): 261-9. 10.1006/jmbi.1996.0248.PubMedCrossRef Ballivet M, Alliod C, Bertrand S, Bertrand D: Nicotinic acetylcholine receptors in the nematode Caenorhabditis elegans. J Mol Biol. 1996, 258 (2): 261-9. 10.1006/jmbi.1996.0248.PubMedCrossRef
43.
go back to reference Fleming JT, Squire MD, Barnes TM, Tornoe C, Matsuda K, Ahnn J, Fire A, Sulston JE, Barnard EA, Sattelle DB, Lewis JA: Caenorhabditis elegans levamisole resistance genes lev-1, unc-29, and unc-38 encode functional nicotinic acetylcholine receptor subunits. J Neurosci. 1997, 17 (15): 5843-57.PubMed Fleming JT, Squire MD, Barnes TM, Tornoe C, Matsuda K, Ahnn J, Fire A, Sulston JE, Barnard EA, Sattelle DB, Lewis JA: Caenorhabditis elegans levamisole resistance genes lev-1, unc-29, and unc-38 encode functional nicotinic acetylcholine receptor subunits. J Neurosci. 1997, 17 (15): 5843-57.PubMed
44.
go back to reference Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R: A C. elegans mutant that lives twice as long as wild type. Nature. 1993, 366 (6454): 461-4. 10.1038/366461a0.PubMedCrossRef Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R: A C. elegans mutant that lives twice as long as wild type. Nature. 1993, 366 (6454): 461-4. 10.1038/366461a0.PubMedCrossRef
45.
go back to reference Tatar M, Kopelman A, Epstein D, Tu MP, Yin CM, Garofalo RS: A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001, 292 (5514): 107-10. 10.1126/science.1057987.PubMedCrossRef Tatar M, Kopelman A, Epstein D, Tu MP, Yin CM, Garofalo RS: A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001, 292 (5514): 107-10. 10.1126/science.1057987.PubMedCrossRef
46.
go back to reference Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y: IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003, 421 (6919): 182-7. 10.1038/nature01298.PubMedCrossRef Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y: IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003, 421 (6919): 182-7. 10.1038/nature01298.PubMedCrossRef
47.
go back to reference Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, Schreiber S, Nebel A: Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci USA. 2009, 106 (8): 2700-5. 10.1073/pnas.0809594106.PubMedPubMedCentralCrossRef Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, Schreiber S, Nebel A: Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci USA. 2009, 106 (8): 2700-5. 10.1073/pnas.0809594106.PubMedPubMedCentralCrossRef
48.
go back to reference Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B, Curb JD: FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008, 105 (37): 13987-92. 10.1073/pnas.0801030105.PubMedPubMedCentralCrossRef Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B, Curb JD: FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008, 105 (37): 13987-92. 10.1073/pnas.0801030105.PubMedPubMedCentralCrossRef
49.
go back to reference Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P: Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA. 2008, 105 (9): 3438-42. 10.1073/pnas.0705467105.PubMedPubMedCentralCrossRef Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P: Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA. 2008, 105 (9): 3438-42. 10.1073/pnas.0705467105.PubMedPubMedCentralCrossRef
50.
go back to reference Buccafusco JJ, Beach JW, Terry AV, Jonnala RR: Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders. Patent Number: 6,881,738; issue date: 04/19/05. Buccafusco JJ, Beach JW, Terry AV, Jonnala RR: Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders. Patent Number: 6,881,738; issue date: 04/19/05.
51.
go back to reference Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS: Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J Biol Chem. 1996, 271 (16): 9390-7. 10.1074/jbc.271.16.9390.PubMedCrossRef Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS: Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J Biol Chem. 1996, 271 (16): 9390-7. 10.1074/jbc.271.16.9390.PubMedCrossRef
52.
go back to reference Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA. 1995, 92 (20): 9368-72. 10.1073/pnas.92.20.9368.PubMedPubMedCentralCrossRef Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA. 1995, 92 (20): 9368-72. 10.1073/pnas.92.20.9368.PubMedPubMedCentralCrossRef
Metadata
Title
Neuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans
Authors
Roongpetch Keowkase
Marwa Aboukhatwa
Bao-Ling Adam
J Warren Beach
Alvin V Terry Jr
Jerry J Buccafussco
Yuan Luo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2010
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-5-59

Other articles of this Issue 1/2010

Molecular Neurodegeneration 1/2010 Go to the issue